Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 22, 2021

Imara updates primary goal of Phase IIb sickle cell disease therapy trial

The endpoint modification is based on a feedback from the FDA on assessing the draft statistical analysis plan of the trial.

Imara has modified the primary goal of the Phase IIb Ardent clinical trial of tovinontrine (IMR-687) in individuals with sickle cell disease (SCD), a rare red blood cell disorder.

The move comes after the US Food and Drug Administration (FDA) provided a written recommendation to change the primary endpoint.

Tovinontrine is a small molecule inhibitor of phosphodiesterase-9 (PDE9).

The international, randomised, placebo-controlled, double-blind, multicentre trial has concluded the target enrolment of nearly 115 adult subjects with SCD, who will receive either tovinontrine or a placebo.

Imara had sought FDA feedback on the draft statistical analysis plan (SAP) for the trial where fetal haemoglobin (HbF) response was the primary goal while the key secondary goal was the annualised rate of vaso-occlusive crises (VOCs).

The FDA subsequently suggested Imara update the primary goal to an annualised rate of VOCs.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Imara noted that HbF response will now become the crucial secondary goal of the trial while its conduct or operational components are unaffected by the endpoint modifications.

Assessment of the impact of tovinontrine against placebo on various VOC-linked outcome measures, markers of red blood cell hemolysis, HbF-related biomarkers, quality of life measures and white blood cell adhesion markers for a year will be the other goals of the trial.

An interim assessment of VOC rates is anticipated to be carried out in the first quarter while final data analysis will be conducted in the second quarter of next year.

Imara president and CEO Rahul Ballal said: “A reduction in VOC rate is an established approval endpoint, and we are engaging the FDA further on this and related topics, including possible streamlined paths to registration.”

“The first review of data from the Ardent trial, including annualized VOC rate, will be conducted when all subjects have completed an assessment at Week 24 or terminated early and are planned for the first quarter of 2022, subject to our upcoming discussions with the FDA.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy